Jamjoom Pharmaceuticals Factory Co (SAU:4015) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Jamjoom Pharmaceuticals Factory Co EBITDA Margin % Related Terms
Jamjoom Pharmaceuticals Factory Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jamjoom Pharmaceuticals Factory Co EBITDA Margin % Chart
SAU:4015 vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jamjoom Pharmaceuticals Factory Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jamjoom Pharmaceuticals Factory Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jamjoom Pharmaceuticals Factory Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Jamjoom Pharmaceuticals Factory Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jamjoom Pharmaceuticals Factory Co (SAU:4015) has a EBITDA Margin % of 39.26% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jamjoom Pharmaceuticals Factory Co and its competitors. This is 25% above median its historical median of 31.50. Over the past decade, Jamjoom Pharmaceuticals Factory Co's EBITDA Margin % has ranged from 23.04 to 36.22. According to the industry distribution chart, Jamjoom Pharmaceuticals Factory Co ranks #80 out of 952 companies in the Drug Manufacturers industry, placing it in the top 8.4%.
Is Jamjoom Pharmaceuticals Factory Co's EBITDA Margin % too high?
Jamjoom Pharmaceuticals Factory Co's current EBITDA Margin % of 39.26% is 25% above median its 10-year median of 31.50. Over the past 10 years, this metric has ranged from a low of 23.04 to a high of 36.22. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Jamjoom Pharmaceuticals Factory Co's value of 39.26% is 214.8% above this industry median. Based on the distribution chart, Jamjoom Pharmaceuticals Factory Co ranks #80 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jamjoom Pharmaceuticals Factory Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jamjoom Pharmaceuticals Factory Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jamjoom Pharmaceuticals Factory Co ranks #80 out of 952 companies for EBITDA Margin %. This places Jamjoom Pharmaceuticals Factory Co in the top 8% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.47. Jamjoom Pharmaceuticals Factory Co's value of 39.26% is 214.8% above this benchmark. Historically, Jamjoom Pharmaceuticals Factory Co's own EBITDA Margin % has ranged from 23.04 to 36.22 over the past decade. While the company's 10-year median is 31.50 vs. the industry median of 12.47, Jamjoom Pharmaceuticals Factory Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jamjoom Pharmaceuticals Factory Co's current EBITDA Margin % of 39.26% is 214.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jamjoom Pharmaceuticals Factory Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jamjoom Pharmaceuticals Factory Co's current EBITDA Margin % is 39.26%, which is 25% above median its own 10-year median of 31.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jamjoom Pharmaceuticals Factory Co stock overvalued right now?
Based on GuruFocus' analysis, Jamjoom Pharmaceuticals Factory Co (SAU:4015) is currently considered Modestly Undervalued. The stock's GF Value™ is ﷼181.57, compared to a current price of ﷼158.40 — trading 12.8% below its estimated fair value. The current EBITDA Margin % is 39.26%, which is 25% above median its 10-year median of 31.50 and 214.8% above the Drug Manufacturers industry median of 12.47. Jamjoom Pharmaceuticals Factory Co's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jamjoom Pharmaceuticals Factory Co (SAU:4015), the current EBITDA Margin % is 39.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jamjoom Pharmaceuticals Factory Co (SAU:4015) Overvalued in 2026?
Based on GuruFocus' analysis, Jamjoom Pharmaceuticals Factory Co stock appears to be undervalued.
The current stock price of ﷼158.40 is trading 12.8% below its estimated GF Value™ of ﷼181.57.
GuruFocus considers Jamjoom Pharmaceuticals Factory Co to be Modestly Undervalued.
Key valuation signals for SAU:4015:
EBITDA Margin %: 39.26% (25% above median its 10-year median of 31.50)
GF Value™: ﷼181.57 vs. price of ﷼158.40 (12.8% below fair value)
Industry Position: 214.8% above the Drug Manufacturers median (#80 of 952)
No single metric tells the full story. See the SAU:4015 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jamjoom Pharmaceuticals Factory Co Business Description
Jamjoom Pharmaceuticals Factory Co is engaged in producing human medicines, nutraceuticals, antibiotics, general analgesics, medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, ulcer and acidity, treatment of various skin infections, cancer diseases, eye drops and ointments and cosmeceuticals. Geographically the company has a presence in the Kingdom of Saudi Arabia, the Gulf, Iraq, Egypt, North Africa, and other export markets.
73GF Score
Get the complete analysis for SAU:4015
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4015 has been successfully added to your 
